Skip to main content

Advertisement

Volume 3 Supplement 1

ESICM LIVES 2015

The effects of ulinastatin in multiple organ failure: a retrospective observational study in a single center ICU

Article metrics

  • 416 Accesses

Introduction

Ulinastatin, an urinary protease inhibitor, might reduce mortality of patients with systemic inflammatory response syndrome such as ARDS [1] and sepsis [2].

Objectives

Our aim was to evaluate the effectiveness of ulinastatin on 28-day mortality among patients with multiple organ failure.

Methods

We conducted a retrospective observational study of patients who were diagnosed multiple organ failure within 24 hours from admission in a general ICU of a tertiary care hospital in Japan. The study duration was from January 2009 to December 2012. The primary outcome was 28-day all cause mortality. The intervention was received ulinastatin for three days and more. Patients were also stratified by category of diseases as subgroup analysis.

Results

A total of 212 patients with multiple organ failure met inclusion criteria during this study period. At baseline, mean age was 66.2 ± 14.7 years old, male was 146/212 (69%), mean APACHE II score was 24.7 ± 7.9, 206/212 (97 %) patients received mechanical ventilation, and 205/212 (96 %) patients were on vasopressor. Overall, 79/212 (37%) patients received ulinastatin. 28-day all cause mortality was 43/212 (20%). There were no significant differences between ulinasatin group and control group in age, gender, APACHE II score. Ulinastatin group had higher prevalence of sepsis (35/79 (44.3%) vs. 29/133 (21.8%), P = 0.001). They were more likely to receive corticosteroid, vasopressor, renal replacement therapy, and veno-arterial extra-corporeal membranous oxygenation (VA-ECMO). The mortality was not significantly different between the ulinastatin group and control group (20/79 (25.3%) vs. 23/133 (17.3%), P = 0.163). In logistic regression after adjusting for APACHE II score, there was not significant difference in the mortality (OR = 1.59; 95% CI, 0.79 - 3.21). The result was similar after adjusting for APACHE II score, sepsis, respiratory disorder, therapeutic interventions including corticosteroid, vasopressor, renal replacement therapy, and VA-ECMO. (OR = 1.29; 95% CI, 0.56 - 2.99). In sepsis patients, ulinastatin did not reduce the mortality, either. (OR = 1.92; 95% CI, 0.52 - 7.13).

Conclusions

Ulinastatin was not associated with survival in patients with multiple organ failure.

References

  1. 1.

    Leng Y-X, et al: Ulinastatin for acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis. World J Crit care Med. 2014, 3: 34-41. 10.5492/wjccm.v3.i1.34.

  2. 2.

    Karnad DR, et al: Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014, 40: 830-8. 10.1007/s00134-014-3278-8.

Download references

Author information

Correspondence to M Uchida.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Uchida, M., Abe, T. & Ono, K. The effects of ulinastatin in multiple organ failure: a retrospective observational study in a single center ICU. ICMx 3, A878 (2015) doi:10.1186/2197-425X-3-S1-A878

Download citation

Keywords

  • Corticosteroid
  • Mechanical Ventilation
  • Respiratory Disorder
  • Renal Replacement Therapy
  • Tertiary Care